Previous Article | Next Article 
Infect Immun, March 1998, p. 1070-1075, Vol. 66, No. 3
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Transcriptional Regulation of Endothelial Cell
Tissue Factor Expression during Rickettsia rickettsii
Infection: Involvement of the Transcription Factor NF-
B
Rui-Jin
Shi,1
Patricia J.
Simpson-Haidaris,1
Norma B.
Lerner,1
Victor J.
Marder,1
David J.
Silverman,2 and
Lee
Ann
Sporn1,*
Vascular Medicine Unit, Department of
Medicine, Department of Pathology and Laboratory Medicine,
Department of Microbiology and Immunology, and Department of
Pediatrics, University of Rochester School of Medicine & Dentistry,
Rochester, New York,1 and
Department of
Microbiology and Immunology, University of Maryland School of
Medicine, Baltimore, Maryland2
Received 2 September 1997/Returned for modification 21 October
1997/Accepted 8 December 1997
 |
ABSTRACT |
The vascular endothelial cell (EC) is a primary target of infection
with Rickettsia rickettsii, the etiologic agent of Rocky Mountain spotted fever. Changes in gene transcription elicited by
intracellular infection, including EC expression of the coagulation pathway initiator known as tissue factor (TF), may contribute to the
vascular pathology observed during disease. Nuclear run-on analysis of
uninfected and infected, cultured human endothelial cells revealed that
the rate of TF mRNA transcription is enhanced more than twofold at
3 h following infection, thus coinciding with increased
steady-state levels of TF mRNA. TF mRNA remained relatively unstable
during infection, with a half-life of 1.6 h. The eukaryotic
protein synthesis inhibitor cycloheximide did not block R. rickettsii-induced increase in TF mRNA levels and actually
resulted in its superinduction, thus revealing that de novo synthesis
of host cell protein was not prerequisite to this transcriptional
response. Involvement of the transcription factor NF-
B in R. rickettsii-induced TF expression was demonstrated by using two
unrelated inhibitors of NF-
B activation. The antioxidant pyrrolidinedithiocarbamate and the proteasome inhibitor
N-tosyl-L-phenylalanine chloromethyl ketone
blocked expression of TF mRNA and activity during infection. This study
demonstrates that R. rickettsii infection results in
transcriptional activation of the TF gene and that this response
involves activation of the transcription factor NF-
B.
 |
INTRODUCTION |
The vascular endothelial cell (EC)
is a primary target of Rickettsia rickettsii infection
during Rocky Mountain spotted fever, and the effects elicited by
intracellular infection of this cell type likely contribute to the
vascular pathology which is a hallmark of disease and which includes
formation of fibrin microthrombi, enhanced vessel permeability, and
vasculitis (38). Considerable experimental evidence exists
to support the notion that in addition to necrotic cell injury, the
R. rickettsii-infected EC alters its production of several
proteins which likely results in presentation of a procoagulant and
proinflammatory phenotype. Evidence for such responses is provided by
studies of cultured EC, in which rickettsial infection cause increased
expression of tissue factor (TF) (33, 36), plasminogen
activator inhibitor 1 (9, 27), E-selectin (31),
interleukin-1 (IL-1) (14, 36), and IL-6 and -8 (14).
TF, a 263-residue membrane glycoprotein, plays a critical role in
initiation of blood coagulation by serving as an essential cofactor for
activation of factor VII (2). TF is not normally expressed
by cells of the vasculature but rather is present in many other
tissues, thus forming a hemostatic envelope to induce coagulation in
the event of vessel disruption (19). TF can be induced in
cultured EC and in monocytes (25), and such expression by
these vascular cells during disease likely results in thrombosis. Since
activation of coagulation and resultant thrombus formation is a common
occurrence in the course of Rocky Mountain spotted fever and may be a
central pathophysiologic occurrence, much effort in our laboratory is
directed toward gaining further understanding of the dynamics and
mechanisms involved in R. rickettsii-induced TF expression.
Except for an apparent requirement for intracellular infection
(33), the mechanisms governing R. rickettsii-induced TF expression, as well as expression of other
rickettsia-induced proteins, have remained elusive. Endothelial TF
expression, which is induced in cultured EC in response to soluble
agonists such as cytokines (5, 6, 18), lipopolysaccharides
(LPSs) (7), and phorbol esters (16), is
controlled by transcriptional and posttranscriptional control
mechanisms (1, 8, 10, 26). Increases in steady-state levels
of TF mRNA in response to these soluble stimuli can occur in the
absence of de novo protein synthesis (8), and thus TF is
often described as an early-response gene. In this report, we analyze
both the transcription rate and stability of TF mRNA during R. rickettsii infection and explore the requirement for de novo host
cell protein synthesis. Further, we document involvement of the
transcription factor NF-
B in R. rickettsii-induced TF expression. These studies provide the first direct evidence for R. rickettsii-induced activation of transcription of an EC
gene and demonstrate that TF behaves as an early-response gene to this novel cell stimulus.
 |
MATERIALS AND METHODS |
EC culture, infection, and drug treatment.
Human umbilical
vein EC were cultured as previously described (11, 38),
using umbilical cords collected within 48 h of delivery. Cells
were cultured in McCoy's 5a medium (Flow Laboratories, McLean, Va.)
containing 20% fetal bovine serum, EC mitogen (50 µg/ml;
Collaborative Research, Inc., Bedford, Mass.), heparin (100 µg/ml),
and insulin (25 µg/ml) (Sigma Chemical Co., St. Louis, Mo.). Cells at
second passage were used in experimental protocols and were plated so
as to achieve 80 to 90% confluency after 5 to 7 days in culture.
R. rickettsii (Sheila Smith strain) was used as a
plaque-purified seed stock (1 × 107 to 5 × 107 PFU/cm2) prepared in Vero cells (African
green monkey kidney; American Type Culture Collection, Rockville, Md.)
(29). EC were infected by using approximately 6 × 104 PFU/cm2 of cell culture area. Infection was
monitored by using EC plated on Thermanox coverslips (Ted Pella Inc.,
Tustin, Calif.) and stained by immunofluorescence using antibody
against R. rickettsii (kindly provided by T. Tzianobos,
Centers for Disease Control, Atlanta, Ga.) as previously described
(32). EC cultures were preincubated with
pyrrolidinedithiocarbamate (PDTC; 25 µM; Sigma) and
N-tosyl-L-phenylalanine chloromethyl ketone
(TPCK; 50 µM; Sigma) for 1 h prior to and during infection.
cDNA probes.
The TF probe was prepared by using the
EcoRI-HindIII fragment corresponding to bases
1 to 1358 subcloned from pKS2b (a kind gift from W. H. Konisberg,
Yale University, New Haven, Conn.) into pGEM7Zf(
) (Promega, Madison,
Wis.). The human
-actin probe was obtained from L. Kedes (Stanford
University, Palo Alto, Calif.). The 2,200-bp BamHI fragment
of
-actin was subcloned into the BamHI site of
pGEM7Zf(
).
Northern blot analysis.
EC cultured in 75-cm2
flasks were infected for 4 h and then lysed with 6.4 ml of
Tri-Reagent (Molecular Research Center, Inc., Cincinnati, Ohio), and
RNA was isolated according to the manufacturer's instructions and
dissolved in distilled water. Twenty micrograms of total RNA per
condition was denatured with glyoxal-dimethyl sulfoxide and then
resolved by electrophoresis in 1.2% agarose gels in 10 mM sodium
phosphate buffer (pH 7.0) (30). Total RNA was prepared for
Northern blot analysis by electrophoretic transfer to Zeta-Probe
membranes (Bio-Rad, Centreville, N.Y.). Probes were labeled with
[
-32P]dCTP, using a random primer labeling kit from
Life Technologies (Gaithersburg, Md.). To determine steady-state levels
of TF or
-actin, hybridization was carried out at 65°C with 0.5 M
Na2HPO4-H3PO4 (pH
7.2)-1 mM EDTA-7% (wt/vol) sodium dodecyl sulfate (SDS), with final
stringency washes carried out as described previously (12). For determination of mRNA stability, EC were infected with R. rickettsii for times indicated, then actinomycin D (20 µg/ml; Sigma) was added, and cultures were incubated at 37°C for additional times prior to RNA extraction and Northern blot analysis. Northern blotting was performed under conditions of probe excess, and several autoradiographic exposures were prepared to ensure that signals were
below saturation. The amount of 18S rRNA was determined by scanning of
a photographic negative prepared following acridine orange staining.
For studies of the requirement for de novo protein synthesis in TF
induction, EC were incubated with cycloheximide (CHX; 10 µg/ml;
Sigma) for 1 h prior to and during infection. Total RNA was
extracted and analyzed as described above.
Nuclear run-on assay.
In vitro measurement of mRNA
transcription rate was carried out by using a modification of
previously described methods (8). Nuclei from approximately
4 × 107 cells/sample were isolated from second- or
third-passage EC by the following method. EC were harvested by brief
exposure to trypsin-EDTA (Gibco Life Technologies, Grand Island, N.Y.),
collected into 15-ml polypropylene tubes, centrifuged at 500 × g for 5 min, and then resuspended in 10 ml of ice-cold
resuspension buffer (RSB; 10 mM Tris-HCl [pH 7.4], 10 mM NaCl, 5 mM
MgCl2, 1 mM phenylmethylsulfonyl fluoride, 5 mM
benzamidine). Cells were centrifuged and resuspended twice in RSB and
then vortexed with gradual addition of 7 ml of lysis buffer (10 mM
Tris-HCl [pH 7.4], 10 mM NaCl, 5 mM MgCl2, 0.5% Nonidet
P-40). Nuclei were pelleted at 500 × g for 5 min, washed twice with RSB, resuspended in 210 µl of storage buffer (50 mM
Tris-HCl [pH 8.0], 40% glycerol, 5 mM MgCl2, 0.1 mM
EDTA), and stored at
70°C. In vitro transcription was carried out
by mixing 200 µl of nuclei with 200 µl of 2× reaction buffer (10 mM Tris-HCl [pH 8.0], 5 mM MgCl2, 4 mM MnCl2,
0.3 M KCl, 10 mM ATP, 10 mM GTP, 10 mM CTP) and 250 µCi of
[
-32P]UTP (3,000 Ci/mmol; New England Nuclear, Boston,
Mass.) for 30 min with shaking at 30°C. A volume of 600 µl of HSB
buffer (10 mM Tris-HCl [pH 7.4], 0.5 M NaCl, 50 mM MgCl2,
2 mM CaCl2) containing 60 U of RQ1 DNase 1 (Promega) and 42 U of rRNasin (Promega) was added, after which the mixture was sheared
by repeated pipetting and then incubated at 37°C for 20 min with
shaking. Finally, 200 µl of Tris-SDS buffer (0.5 M Tris-HCl [pH
7.4], 125 mM EDTA, 5% SDS) containing 500 µg of proteinase K (Gibco
Life Technologies) was added to each reaction mixture and incubated at
37°C for 45 min with shaking. Labeled RNA was isolated by
phenol-chloroform extraction and ethanol precipitation and resuspended
in 100 µl of H2O containing 100 µl of S256 [100 µg
of yeast RNA, 4 µg of poly(A), 4 µg of poly(C), and 25 µg of
salmon sperm DNA in 100 ml of 33 mM Tris-HCl buffer (pH 8.0)]. Samples
were boiled for 5 min to denature and quenched on ice. Target cDNAs
were denatured in 0.4 M NaOH-10 mM EDTA, boiled for 10 min, and then
quenched on ice, and an equal volume of ice-cold 2 M ammonium acetate
(pH 7.0) was added to neutralize. The target cDNA (200 µl) was
applied to Zeta-Probe membranes by using a slot blotter (Biodot SF;
Bio-Rad Laboratories, Hercules, Calif.), UV cross-linked, and
prehybridized with 0.5 M
Na2HPO4-H3PO4 (pH
7.2)-1 mM EDTA-7% SDS for 1 h at 65°C with shaking. Membranes
were hybridized with an equivalent amount of denatured, labeled RNA
(1 × 106 to 5 × 106 cpm/ml) at
65°C for 72 h, then washed as described for Northern blot
analysis, and exposed to X-Omat AR film (Eastman Kodak, Rochester, N.Y.) at
70°C.
Isolation of nuclei extraction, and gel shift assay.
Following infection with R. rickettsii, nuclei were isolated
and nuclear proteins were extracted as previously described (13, 15), using approximately 5 × 106 EC per
experimental condition. The protein concentration in the nuclear
extract was measured by using Bradford reagent. This procedure typically yielded protein concentrations between 1 and 2 mg/ml. HeLa
cell nuclear extracts used as controls were obtained from Promega. Gel
shift assays were performed by using the Promega gel shift assay system
as instructed by the manufacturer, using 1 to 2 µg of protein
obtained from the nuclear extractions for each gel shift reaction.
Sequences of double-stranded consensus oligonucleotides used in the gel
shift reactions were as follows: NF-
B (Promega), 5'-AGT TGA GGG GAC
TTT CCC AGG C-3'; and AP-1 (Promega), 5'-CGC TTG ATG AGT CAG CCG
GAA-3'. Probe labeling was carried out according to the manufacturer's
instructions, using [
-32P]ATP (3,000 Ci/mmol; 10 mCi/ml; DuPont NEN Research Products, Boston, Mass.). Competition
studies were performed with a 10-fold molar excess of unlabeled
oligonucleotides added to reaction mixtures prior to addition of
radiolabeled oligonucleotides. Reaction mixtures were analyzed on 4%
nondenaturing, polyacrylamide gels prepared with 0.5× TBE (89 mM
Tris-HCl [pH 8.0], 89 mM boric acid, 2 mM EDTA). The running buffer
was 0.5× TBE. Gels were electrophoresed at 100 V for 3 h, and
autoradiographic exposure of gels was for 12 to 18 h.
Semiquantitative RT-PCR.
Total cellular RNA was isolated
from EC cultured in 25-cm2 flasks, using Tri-Reagent
(Molecular Research Center) as instructed by the manufacturer. Total
RNA (0.5 µg) was reverse transcribed by using Superscript RNase H
reverse transcriptase (10 U; BRL, Gaithersburg, Md.) with
oligo(dT)16 (2.5 µM) in a 20-µl reaction of 5 mM
MgCl2, PCR Buffer II (Perkin-Elmer, Madison, Wis.), 1 mM
each of all four deoxynucleoside triphosphates, and RNase inhibitor (1 U) (Perkin-Elmer) and amplified by using a Gene Amp PCR System 9600 (Perkin-Elmer). Cycles consisted of an initial incubation at 95°C for
105 s and then cycling at 95°C for 30 s, 65°C for 30 s, and 72°C for 60 s, with a final incubation at 72°C for 7 min. For detection of I
B
mRNA, 15 µl of the reverse
transcription reaction (RT) was amplified in a 100-µl reaction
mixture. The primers used were as follows: I
B
forward primer,
5'-GCT CGG AGC CCT GGA AGC-3'; I
B
reverse primer, 5'-GCC CTG GTA
GGT AAC TCT-3' (566-bp product); TF forward primer, 5'-ACT CCC CAG AGT TCA CAC CTT ACC-3'; and TF reverse primer, 5'-TGA CCA CAA ATG CCA CAG
CTC C-3' (398-bp product). To normalize among samples, 2 µl of RT was
amplified in a 100-µl reaction mixture, using primers for the
housekeeping species glyceraldehyde-3-phosphate dehydrogenase (GAPDH):
forward primer, 5'-CCA CCC ATG GCA AAT TCC ATG GCA-3'; and reverse
primer, 5'-TCT AGA CGG CAG GTC AGG TCC ACC-3' (588-bp product). To
ensure that the PCR amplification had not reached plateau phase, the
amplification products were compared following completion of 25, 30, and 35 cycles. Aliquots of PCR products were compared with a 1-kb DNA
ladder (BRL), separated by electrophoresis on a 1.5% agarose gel, and
visualized by ethidium bromide staining.
Assay of TF activity.
EC cultured in 12-well culture plates
were washed twice with Tris-buffered saline (0.05 M Tris, 0.1 M NaCl
[pH 7.5]) and lysed in 0.16 ml of Tris-buffered saline with 10 mg of
bovine serum albumin per ml. After repeated freeze-thawing, TF activity
in the lysed cell sample was assayed using a two-stage clotting assay as previously described (32), and results were determined
based on a standard curve generated by using pure human brain TF
reconstituted into phospholipid vesicles as previously described
(3, 23).
 |
RESULTS |
Nuclear run-on experiments were conducted to determine if R. rickettsii infection of EC increased the rate of transcription of
the TF gene. Nuclei were extracted from uninfected and infected EC, in
vitro transcription was conducted with 32P-labeled UTP, and
then radiolabeled products were hybridized with TF and
-actin cDNA
probes and with plasmid vector alone. The intensity of labeled actin
mRNA in infected and uninfected EC was equivalent, yet intensity of
labeled TF mRNA was increased (2.5-fold higher than the control value
in this representative experiment), indicating an enhanced rate of
transcription of the TF gene (Fig. 1).
This observation is consistent with the increased steady-state level of
TF mRNA observed at 4 h following R. rickettsii infection (32). The transcription inhibitor actinomycin D
(10 µg/ml), when present during infection, completely blocked
R. rickettsii-induced expression of TF activity as measured
by a two-stage clotting assay (not shown), providing further evidence
that a transcriptional event even is necessary for R. rickettsii-induced expression of TF.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 1.
Nuclear run-on assay for TF mRNA transcription rate in
control and R. rickettsii (RR)-infected EC. In vitro
transcription was carried out on nuclei isolated from 3-h-infected EC,
using 32P-labeled UTP, and then radiolabeled RNA was
hybridized with immobilized target cDNA (TF, actin, or the
pGEM-7Zf cloning vector lacking an insert). No detectable
hybridization occurred with the pGEM-7Zf cloning vector
alone.
|
|
The half-life of TF mRNA in infected EC was measured to determine if
mRNA stability was prolonged at the times of peak increases in
steady-state mRNA levels. EC were infected for 3 h, and then actinomycin D (10 µg/ml) was added to inhibit further transcription. Total cellular RNA was harvested following further incubation for
various time intervals and subjected to Northern blot analysis (Fig.
2A). TF mRNA content was quantitated by
densitometric scanning and normalized to the amount of 18S rRNA.
Scanning data, shown plotted on a linear scale in Fig. 2B, were
subsequently linearized on semilog plots and subjected to regression
analysis to calculate half-life values. TF mRNA in infected EC (0 h)
was highly unstable, with a calculated half-life of approximately
1.6 h, based on a regression line with an r value of
0.993. Stability of TF mRNA in uninfected EC could not be determined
since this mRNA was present at undetectable levels. R. rickettsii infection did not alter that half-life of the
housekeeping mRNA species
-actin, which was determined to be
9.5 h (data not shown). Therefore, change in stability of mRNA
species was not a general cellular phenomenon.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 2.
Stability of TF mRNA in R. rickettsii-infected and uninfected EC. Actinomycin D (10 µg/ml)
was added to EC 4 h after infection to inhibit further
transcription, and then TF mRNA (2.2 kb) was analyzed by Northern
blotting following incubation times of 0, 1, 2, 3, and 5 h (A). TF
mRNA remaining at these time points was determined by densitometric
scanning, the results of which were normalized to amounts of 18S rRNA
contained in each sample and then expressed graphically in arbitrary
units of optical density (B).
|
|
The requirement for de novo host cell protein synthesis in R. rickettsii-induced expression of TF mRNA was explored by using the
eukaryotic protein synthesis inhibitor CHX (10 µg/ml) (Fig. 3). EC were infected in the presence and
absence of CHX, treatment which does not inhibit entry of the organisms
into EC (31). Consistent with the previously reported
observation (8), Northern blot analysis of TF mRNA at 4 h demonstrated appearance of TF factor mRNA with CHX treatment alone
(lane 2), whereas untreated EC contained nearly undetectable levels
(lane 1). This effect of CHX treatment may derive from stabilization of
this highly labile mRNA species or from enhanced transcription rate.
R. rickettsii infection alone resulted in the appearance of
TF mRNA (lane 3); however, superinduction occurred when CHX was present
during infection (lane 4). This result indicated that induction of TF
expression during infection occurred independently of de novo host cell
protein synthesis, and thus host cell signalling involved in this
response did not involve synthesis of a protein intermediate.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 3.
Effect of CHX on EC expression of TF mRNA during
R. rickettsii infection. The eukaryotic protein synthesis
inhibitor CHX (10 µg/ml) was added to EC cultures during infection
with R. rickettsii (RR) for 4 h, and then mRNA levels
were determined by Northern blot analysis. Blots were then stripped and
rehybridized with a cDNA probe against the housekeeping species human
-actin. C, control.
|
|
TF expression in cultured EC induced by various soluble agonists is
dependent on activation of members of the NF-
B/Rel family of
transcription factors (20-22), and it was recently reported that infection of cultured EC with R. rickettsii results in
activation of NF-
B (33). To explore involvement of
NF-
B activation in R. rickettsii-induced expression of
TF, we used two inhibitors of NF-
B activation, the antioxidant PDTC
(25 µM) (4, 20) and the proteasome inhibitor TPCK (50 µM) (17). Neither agent affected the initial rate of
infection (Table 1) or resulted in any
obvious changes in morphology of the infected cells (Fig. 4). Both agents were effective at
blocking R. rickettsii-induced activation of NF-
B (Fig.
5A), which appears as two gel-shifted complexes representing a p50 homodimer (C1) and a p50-p65 heterodimer (C2) (24, 34), as determined by gel shift assay using a
32P-labeled oligonucleotide probe corresponding to the
B
binding domain of the murine kappa light-chain gene enhancer and as
measured at 3 h following the initiation of infection. These
compounds specifically inhibited NF-
B activation, as there was no
inhibitory effect on the level of activation of the unrelated
transcription factor, AP-1 (not shown). TPCK (Fig. 5B) and PDTC (not
shown), when present during infection, blocked R. rickettsii-induced NF-
B activation and prevented R. rickettsii-induced increases in steady-state levels of EC I
B
mRNA, as determined by RT-PCR analysis. Increased I
B
mRNA is a
sensitive indicator of NF-
B activation since four NF-
B sites are
present in its promoter region (17, 35).

View larger version (67K):
[in this window]
[in a new window]
|
FIG. 4.
Immunofluorescence staining of R. rickettsii-infected EC. EC cultured on plastic coverslips were
infected for 6 h in the absence (a) or presence (b) of the
proteasome inhibitor TPCK. Coverslips were then fixed and stained by
fluorescence using polyclonal anti-R. rickettsii antibody.
Arrowheads point to R. rickettsii organisms. Bar = 20 µm.
|
|

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 5.
Effect of PDTC and TPCK on R. rickettsii-induced activation of the transcription factor,
NF- B. (A) Activated NF- B (C1 and C2) was assayed by gel shift
assay of nuclear extracts prepared from uninfected EC (C), R. rickettsii-infected EC (RR), and infected EC in the presence of
PDTC (RR+PDTC) or TPCK (RR+TPCK). C3 represents a nonspecific complex
(24, 34). (B) Steady-state levels of I B mRNA (566-bp
product) and of the housekeeping mRNA species GAPDH (588-bp product)
were assayed by RT-PCR in total RNA samples prepared from uninfected EC
(C), infected EC (RR), and infected EC in the presence of TPCK
(RR+TPCK). Shown are amplification products generated following 30 amplification cycles.
|
|
NF-
B inhibition by PDTC and TPCK was used to determine if activation
of this transcription factor participated in R. rickettsii-induced expression of TF mRNA and activity. PDTC and
TPCK treatment during infection resulted in abrogation of R. rickettsii-induced expression of TF mRNA, as measured by RT-PCR
analysis (Fig. 6A). A two-stage clotting
assay was used to measure levels of TF procoagulant activity present in
uninfected and infected cell lysates. While R. rickettsii infection alone resulted in a nearly 10-fold increase in TF activity, such expression was nearly completely inhibited by PDTC or TPCK (Fig.
6B).

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 6.
Effects of PDTC and TPCK on R. rickettsii-induced expression of TF mRNA and TF activity. (A)
Levels of TF mRNA (398-bp product) and GAPDH mRNA (588-bp product) were
analyzed in total RNA samples prepared from uninfected EC (C), R. rickettsii-infected EC, (RR), and infected EC in the presence of
PDTC (RR+PDTC) or TPCK (RR+TPCK) by RT-PCR analysis using specific
primer pairs. Shown are amplification products generated following 30 amplification cycles. (B) TF activity was measured in EC lysates
prepared from uninfected EC (control) and from infected EC (R. rickettsii) alone (open bars) or in the presence of PDTC (25 µM)
(lightly shaded bars) or TPCK (50 µM) (heavily shaded bars) by a
two-stage clotting assay. Mean and standard error of the mean are
indicated; results shown were obtained from three to nine
experiments.
|
|
 |
DISCUSSION |
Superimposed on the necrotic cell injury that occurs during
infection of EC with R. rickettsii (28), the EC
actively responds to infection by altering production of several
protein factors which may contribute to the vascular changes that occur
during disease. There exists little information as to the mechanism(s) by which the presence of this intracellular pathogen elicits such a
response of the host cell or in fact as to whether transcriptional activation of the host cell is a component of this response. The present study provides the first direct evidence for transcriptional activation of a host cell gene during infection and implicates involvement of activation of the transcription factor NF-
B in this
transcriptional response.
Both transcriptional and posttranscriptional control mechanisms have
been shown to influence steady-state levels of TF mRNA in response to
soluble stimuli; however, the relative contribution of each of these
control mechanisms is difficult to discern. An increased rate of
transcription of the TF gene occurs in EC in response to phorbol
myristate acetate (8, 26), tumor necrosis factor
(26), and oxidized low-density lipoprotein (10).
In contrast, LPS influences posttranscriptional control mechanisms, resulting in enhanced stability that likely derives from the presence of an AU-rich region in the 3' untranslated region of TF mRNA, which
allows for modulation of mRNA stability by inhibitors of transcription
and translation (1). It has been reported that LPSs exert no
influence on transcription rate (26), but the half-life of
TF mRNA has been shown to vary from 2 h during the rapid rise in
TF mRNA levels to only 10 min at times when levels decline
(8). Our nuclear run-on experiments (Fig. 1) demonstrate that R. rickettsii infection induces an increase in
transcription rate of TF mRNA at 4 h of infection, coinciding with
the occurrence of peak steady-state levels of TF mRNA. However, at
3 h of infection, a time point at which steady-state levels of TF
mRNA were increasing, the half-life of TF mRNA was approximately
1.6 h (Fig. 2), which is similar to that noted after EC
stimulation with tumor necrosis factor or phorbol ester (1).
Since TF mRNA is not present in uninfected EC, we were unable to
determine whether the value of 1.6 h during infection represented
a significant change over baseline.
The eukaryotic protein synthesis inhibitor CHX was used to determine if
de novo host cell protein synthesis was required for induction of TF
mRNA during R. rickettsii infection. Although CHX alone
resulted in increases in steady-state TF mRNA levels, the combination
with R. rickettsii resulted in superinduction (Fig. 3). This
result indicated that host cell protein synthesis is not required in
the signal transduction pathways involved in TF expression during
infection and that TF behaves as an early-response gene to infection.
R. rickettsii-induced TF expression, therefore, results
largely from direct activation of host cell signal transduction pathways induced by the R. rickettsii organism rather than
by an autocrine feedback system involving a newly synthesized protein intermediate. This conclusion supports our previous observation of only
partial inhibition of TF expression upon inhibition of autocrine cell
stimulation by IL-1 (33).
It was recently reported that activation of members of the NF-
B/Rel
family of transcription factors occurs during R. rickettsii infection of EC (34), and it is postulated that such
activation may participate in changes in gene expression during
infection. TF expression induced by a variety of soluble mediators is
dependent on activation of members of this transcription factor family, and TF expression can be inhibited by using antioxidants and proteasome inhibitors to block NF-
B activation (20-22). PDTC, an
antioxidant, functions to inhibit an obligatory step in the NF-
B
activation pathway requiring a reactive oxygen species (4).
TPCK, an inhibitor of a chymotryptic activity associated with
the proteasome, blocks activation of NF-
B by inhibiting
proteasome-dependent degradation of inhibitory peptides
(17). These chemically unrelated compounds were both
effective at blocking R. rickettsii-induced activation of
NF-
B (Fig. 5). Consequently, they blocked R. rickettsii-induced increases in TF mRNA and activity (Fig. 6),
thus implicating NF-
B activation in R. rickettsii-induced
expression of TF. This demonstration of involvement of NF-
B is
consistent with the absence of a requirement for de novo host cell
protein synthesis (Fig. 3), since the NF-
B-I
B complex exists in
a preformed yet inactive pool within the host cell cytoplasm
(17), and thus its activation can occur even in the presence
of protein synthesis inhibitors.
Results of these studies both provide evidence for transcriptional
activation of the EC TF gene during R. rickettsii infection and demonstrate a role for the transcription factor NF-
B.
Furthermore, that R. rickettsii-induced increases in TF mRNA
occur independently of de novo host cell protein synthesis identifies
TF as an early-response gene to this novel intracellular stimulus.
Little is known about intracellular signals generated during
intracellular R. rickettsii infection that may give rise to
such a cellular response, but these results suggest that they likely
mimic those induced during physiologic stimulation such as by cytokines
and growth factors. Further studies of signal transduction and
transcription factor activation during infection will provide valuable
insight into the mechanisms controlling altered host cell gene
expression during R. rickettsii infection.
 |
ACKNOWLEDGMENTS |
We thank Laura Triou, Laura Hansen, Sarah Lawrence, Terrence
Bissoondial, Li Hua Rong, Lisa Domotor, and June Hong for excellent technical assistance and Carol Weed for help in preparation of the
manuscript.
This work was supported in part by grants 30616 and 50615 from the
National Heart, Lung, and Blood Institute (NHLBI), grants 17416 and
40689 from the National Institute of Allergy and Infectious Diseases,
and NHLBI training grant 07152 (R.-J. Shi).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Vascular
Medicine Unit, P.O. Box 610, University of Rochester Medical Center,
601 Elmwood Ave., Rochester, NY 14642. Phone: (716) 275-0439. Fax:
(716) 473-4314. E-mail:
Lee_Ann_Sporn{at}medicine.rochester.edu.
Editor: R. E. McCallum
 |
REFERENCES |
| 1.
|
Ahern, S. M.,
T. Miyata, and J. E. Sadler.
1993.
Regulation of human tissue factor expression by mRNA turnover.
J. Biol. Chem.
268:2154-2159[Abstract/Free Full Text].
|
| 2.
|
Bach, R.
1988.
Initiation of coagulation by tissue factor.
Crit. Rev. Biochem.
23:339-368[Medline].
|
| 3.
|
Bach, R.,
R. Gentry, and Y. Nemerson.
1986.
Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidyl serine.
Biochemistry
25:4007-4020[Medline].
|
| 4.
|
Beg, A. A.,
T. S. Finco,
P. V. Nantermet, and A. S. Baldwin, Jr.
1993.
Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I B : a mechanism for NF- B activation.
Mol. Cell. Biol.
13:3301-3310[Abstract/Free Full Text].
|
| 5.
|
Bevilacqua, M. P.,
J. S. Pober,
G. R. Majeau,
R. S. Cotran, and M. A. Gimbrone.
1984.
Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells.
J. Exp. Med.
160:618-623[Abstract/Free Full Text].
|
| 6.
|
Bevilacqua, M. P.,
J. S. Pober,
G. R. Majeau,
W. Fiers,
R. S. Cotran, and M. A. Gimbrone.
1986.
Recombinant tumor necrosis factor induced procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin.
Proc. Natl. Acad. Sci. USA
83:4533-4537[Abstract/Free Full Text].
|
| 7.
|
Colucci, J.,
G. Balconi,
R. Lorenzet,
A. Pietra,
D. Locati,
M. B. Donati, and N. Semararo.
1983.
Cultured human endothelial cells generate tissue factor in response to endotoxin.
J. Clin. Invest.
71:1893-1896.
|
| 8.
|
Crossman, D. C.,
D. P. Carr,
E. G. D. Tuddenham,
J. D. Pearson, and J. H. McVey.
1990.
The regulation of tissue factor mRNA in human endothelial cells in response to endotoxin or phorbol ester.
J. Biol. Chem.
265:9782-9787[Abstract/Free Full Text].
|
| 9.
|
Drancourt, M.,
M.-C. Alessi,
P.-Y. Levy,
I. Juhan-Vague, and D. Raoult.
1990.
Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by Rickettsia conorii- and Rickettsia rickettsii-infected cultured endothelial cells.
Infect. Immun.
58:2459-2463[Abstract/Free Full Text].
|
| 10.
|
Fei, H.,
J. A. Berliner,
F. Parhami, and T. A. Drake.
1993.
Regulation of endothelial cell tissue factor expression by minimally oxidized LDL and lipopolysaccharide.
Arterioscler. Thromb.
13:1711-1717[Abstract/Free Full Text].
|
| 11.
|
Gimbrone, M. A., Jr.,
R. S. Cotran, and J. Folkman.
1974.
Human vascular endothelial cells in culture. Growth and DNA synthesis.
J. Cell Biol.
60:673-680[Abstract/Free Full Text].
|
| 12.
|
Haidaris, P. J.,
T. W. Wright,
F. Gigliotti, and C. G. Haidaris.
1992.
Expression and characterization of a cDNA clone encoding an immunodominant surface glycoprotein of Pneumocystis carinii.
J. Infect. Dis.
166:1113-1123[Medline].
|
| 13.
|
Hanss, M., and D. Collen.
1987.
Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: modulation by thrombin, endotoxin, and histamine.
J. Lab. Clin. Med.
109:97-104[Medline].
|
| 14.
|
Lissitsky, J.-M.,
Durand,
J. Soubeyrand,
C. A. Dinarello, and P. Bongrand.
1995.
IL-6 and IL-8 production from cultured human endothelial cells stimulated by infection with Rickettsia conorii via a cell-associated IL-1 -dependent pathway.
J. Clin. Invest.
96:2839-2844.
|
| 15.
|
Loskutoff, D. J.,
M. Sawdey, and J. Mimuro.
1989.
Type 1 plasminogen activator inhibitor, p. 87-115. In
B. Coller (ed.), Progress in hemostasis and thrombosis, vol. 9.
W. B. Saunders, Philadelphia, Pa.
|
| 16.
|
Lyberg, T.,
K. S. Galdal,
S. A. Evensen, and H. Prydz.
1983.
Cellular cooperation in endothelial cell thromboplastin synthesis.
Br. J. Haematol.
53:85-90[Medline].
|
| 17.
|
Miyamoto, S., and I. M. Verma.
1995.
REL/NF- B/I B story.
Adv. Cancer Res.
66:255-292[Medline].
|
| 18.
|
Nawroth, P., and D. Stern.
1986.
Modulation of endothelial cells hemostatic properties by tumor necrosis factor.
J. Exp. Med.
163:740[Abstract/Free Full Text].
|
| 19.
|
Nemerson, Y.
1988.
Tissue factor and hemostasis.
Blood
71:1-8[Free Full Text].
|
| 20.
|
Orthner, C. L.,
G. M. Rodgers, and L. A. Fitzgerald.
1995.
Pyrrolidine dithiocarbamate abrogates tissue factor (TF) expression by endothelial cells: evidence implicating nuclear factor- B in TF induction by diverse agonists.
Blood
86:436-443[Abstract/Free Full Text].
|
| 21.
|
Parry, G. C. N., and N. Mackman.
1994.
A set of inducible genes expressed by activated human monocytic and endothelial cells contain B-like sites that specifically bind c-Rel-p65 heterodimers.
J. Biol. Chem.
269:20823-20825[Abstract/Free Full Text].
|
| 22.
|
Parry, G. C. N., and N. Mackman.
1995.
Transcriptional regulation of tissue factor expression in human endothelial cells.
Arterioscler. Thromb. Vasc. Biol.
15:612-621[Abstract/Free Full Text].
|
| 23.
|
Pitlick, F. A., and Y. Nemerson.
1976.
Purification and characterization of tissue factor apoprotein.
Methods Enzymol.
45:37-42[Medline].
|
| 24.
|
Read, M. A.,
M. Z. Whitley,
A. J. Williams, and T. Collins.
1994.
NF- B and I B : an inducible regulatory system in endothelial activation.
J. Exp. Med.
179:503-512[Abstract/Free Full Text].
|
| 25.
|
Ruf, W., and T. S. Edgington.
1994.
Structural biology of tissue factor, the initiator of thrombogenesis in vivo.
FASEB J.
8:385-390[Abstract].
|
| 26.
|
Schleef, R. R.,
M. P. Bevilacqua,
M. Sawdey,
M. A. Gimbrone, Jr., and D. J. Loskutoff.
1988.
Cytokine activation of vascular endothelium.
J. Biol. Chem.
263:5797-5803[Abstract/Free Full Text].
|
| 27.
|
Shi, R.-J.,
P. J. Simpson-Haidaris,
V. J. Marder, and D. J. Silverman.
1996.
Increased expression of plasminogen activator inhibitor-1 in R. rickettsii-infected endothelial cells.
Thromb. Haemostasis
75:600-606[Medline].
|
| 28.
|
Silverman, D. J.
1986.
Infection and injury of human endothelial cells by Rickettsia rickettsii.
Ann. Inst. Pasteur/Microbiol.
137A:336-341.
|
| 29.
|
Silverman, D. J., and L. A. Santucci.
1988.
Potential for free radical-induced lipid peroxidation as a cause of endothelial cell injury in Rocky Mountain spotted fever.
Infect. Immun.
56:3110-3115[Abstract/Free Full Text].
|
| 30.
|
Simpson, P. J.
1987.
An improved method for mRNA isolation and characterization of in vitro translation products by Western blotting.
Gene
56:161-171[Medline].
|
| 31.
|
Sporn, L. A.,
S. A. Lawrence,
D. J. Silverman, and V. J. Marder.
1993.
E-selectin-dependent neutrophil adhesion to Rickettsia rickettsii-infected endothelial cells.
Blood
81:2406-2412[Abstract/Free Full Text].
|
| 32.
|
Sporn, L. A.,
P. J. Haidaris,
R.-J. Shi,
Y. Nemerson,
D. J. Silverman, and V. J. Marder.
1994.
Rickettsia rickettsii infection of cultured human endothelial cells induces tissue factor expression.
Blood
83:1527-1534[Abstract/Free Full Text].
|
| 33.
|
Sporn, L. A., and V. J. Marder.
1996.
Interleukin-1 production during Rickettsia rickettsii infection of cultured endothelial cells: potential role in autocrine cell stimulation.
Infect. Immun.
64:1609-1613[Abstract].
|
| 34.
|
Sporn, L. A.,
S. K. Sahni,
N. B. Lerner,
V. J. Marder,
D. J. Silverman,
L. C. Turpin, and A. L. Schwab.
1997.
Rickettsia rickettsii infection of cultured human endothelial cells induces NF- B activation.
Infect. Immun.
65:2786-2791[Abstract].
|
| 35.
|
Sun, S.-C.,
P. A. Ganchi,
D. W. Ballard, and W. C. Greene.
1993.
NF- B controls expression of inhibitor I B : evidence for an inducible autoregulatory pathway.
Science
259:1912-1915[Abstract/Free Full Text].
|
| 36.
|
Teysseire, N.,
D. Arnoux,
F. George,
J. Sampol, and D. Raoult.
1992.
von Willebrand factor release, thrombomodulin activity and tissue factor expression in Rickettsia conorii-infected endothelial cells.
Infect. Immun.
60:4388-4393[Abstract/Free Full Text].
|
| 37.
|
van den Berg, E. A.,
E. D. Sprengers,
M. Jaye,
W. Burgess,
T. Maciag, and V. W. M. van Hinsbergh.
1988.
Regulation of plasminogen activator inhibitor-1 mRNA in human endothelial cells.
Thromb. Haemostasis
60:63-67[Medline].
|
| 38.
|
Wagner, D. D.,
J. B. Olmsted, and V. J. Marder.
1982.
Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells.
J. Cell Biol.
95:355-360[Abstract/Free Full Text].
|
| 39.
|
Woodward, W. E., and R. B. Hornick.
1990.
Infectious diseases and their etiologic agents, p. 1082-1100. In
G. L. Mandell, R. G. Doublas, Jr., and J. E. Bennett (ed.), Principles and practice of infectious diseases.
Churchill Livingston, New York, N.Y.
|
Infect Immun, March 1998, p. 1070-1075, Vol. 66, No. 3
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Rydkina, E., Sahni, A., Silverman, D. J., Sahni, S. K.
(2007). Comparative analysis of host-cell signalling mechanisms activated in response to infection with Rickettsia conorii and Rickettsia typhi. J Med Microbiol
56: 896-906
[Abstract]
[Full Text]
-
Rydkina, E., Sahni, A., Baggs, R. B., Silverman, D. J., Sahni, S. K.
(2006). Infection of Human Endothelial Cells with Spotted Fever Group Rickettsiae Stimulates Cyclooxygenase 2 Expression and Release of Vasoactive Prostaglandins. Infect. Immun.
74: 5067-5074
[Abstract]
[Full Text]
-
Duan, H. O., Simpson-Haidaris, P. J.
(2006). Cell Type-specific Differential Induction of the Human {gamma}-Fibrinogen Promoter by Interleukin-6. J. Biol. Chem.
281: 12451-12457
[Abstract]
[Full Text]
-
Clifton, D. R., Rydkina, E., Freeman, R. S., Sahni, S. K.
(2005). NF-{kappa}B Activation during Rickettsia rickettsii Infection of Endothelial Cells Involves the Activation of Catalytic I{kappa}B Kinases IKK{alpha} and IKK{beta} and Phosphorylation-Proteolysis of the Inhibitor Protein I{kappa}B{alpha}. Infect. Immun.
73: 155-165
[Abstract]
[Full Text]
-
Radulovic, S., Price, P. W., Beier, M. S., Gaywee, J., Macaluso, J. A., Azad, A.
(2002). Rickettsia-Macrophage Interactions: Host Cell Responses to Rickettsia akari and Rickettsia typhi. Infect. Immun.
70: 2576-2582
[Abstract]
[Full Text]
-
Cho, N.-H., Seong, S.-Y., Choi, M.-S., Kim, I.-S.
(2001). Expression of Chemokine Genes in Human Dermal Microvascular Endothelial Cell Lines Infected with Orientia tsutsugamushi. Infect. Immun.
69: 1265-1272
[Abstract]
[Full Text]
-
Tapper, H., Herwald, H.
(2000). Modulation of hemostatic mechanisms in bacterial infectious diseases. Blood
96: 2329-2337
[Full Text]
-
Haynes, R. J., McElveen, J. E., Dua, H. S., Tighe, P. J., Liversidge, J.
(2000). Expression of Human Beta-Defensins in Intraocular Tissues. IOVS
41: 3026-3031
[Abstract]
[Full Text]
-
Sahni, S. K., Turpin, L. C., Brown, T. L., Sporn, L. A.
(1999). Involvement of Protein Kinase C in Rickettsia rickettsii-Induced Transcriptional Activation of the Host Endothelial Cell. Infect. Immun.
67: 6418-6423
[Abstract]
[Full Text]
-
Dechend, R., Maass, M., Gieffers, J., Dietz, R., Scheidereit, C., Leutz, A., Gulba, D. C.
(1999). Chlamydia pneumoniae Infection of Vascular Smooth Muscle and Endothelial Cells Activates NF-{kappa}B and Induces Tissue Factor and PAI-1 Expression : A Potential Link to Accelerated Arteriosclerosis. Circulation
100: 1369-1373
[Abstract]
[Full Text]
-
Sahni, S. K., Van Antwerp, D. J., Eremeeva, M. E., Silverman, D. J., Marder, V. J., Sporn, L. A.
(1998). Proteasome-Independent Activation of Nuclear Factor kappa B in Cytoplasmic Extracts from Human Endothelial Cells by Rickettsia rickettsii. Infect. Immun.
66: 1827-1833
[Abstract]
[Full Text]